Market Price

51.87 

1.56 3.1%

as of Apr 03 '20

52 Week Range:

38.12 61.81


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in hematology, oncology, immunology, cardiovascular, and fibrotic diseases. It provides Revlimid and Pomalyst/Imnovid, which are oral immunomodulatory drugs used to treat multiple myeloma; Eliquis, an oral inhibitor for stroke prevention and venous thromboembolic disorders; Opdivo, a biological product for anti-cancer indications; and Orencia, a biological product for patients with active RA and prostate-specific antigen and active polyarticular juvenile idiopathic arthritis. The company also offers Sprycel, a tyrosine kinase inhibitor to treat Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody to treat unresectable or metastatic melanoma; Abraxane, a chemotherapy product used to treat breast, non-small cell lung, and pancreatic cancers; and Reblozyl, an erythroid maturation agent to treat anemia. In addition, it provides Inrebic, a kinase inhibitor to treat myelofibrosis; Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Baraclude, an oral antiviral agent to treat chronic hepatitis B; and Vidaza, a pyrimidine nucleoside analog to treat refractory anemia and chronic myeloid leukemia. The company sells products to wholesalers, specialty distributors, retail pharmacies, hospitals, government entities, and medical profession. Bristol-Myers Squibb Company has collaboration agreements with Ono; AbbVie; Nektar Therapeutics; Five Prime Therapeutics, Inc.; Exelixis, Inc.; Janssen Pharmaceuticals, Inc.; Nitto Denko Corporation; GeMoaB Monoclonals GmbH; bluebird bio, Inc.; Acceleron Pharma Inc.; Agios Pharmaceuticals, Inc.; Ikena Oncology, and Pfizer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Equity (BVPS) 5.92
6.97
7.59
6.44
6.53
7.54
8.31
8.88
7.62
7.35
7.08
growth rate 17.7% 8.9% -15.2% 1.4% 15.5% 10.2% 6.9% -14.2% -3.5% -3.7%
Earnings BIT 4,415.04
4,785.59
5,503.03
1,844.86
2,278.48
3,468.00
3,867.00
5,187.00
3,980.00
6,415.00
7,064.00
growth rate 8.4% 15.0% -66.5% 23.5% 52.2% 11.5% 34.1% -23.3% 61.2% 10.1%
Avg.PE 14.60
15.11
12.59
27.55
34.72
43.55
60.43
19.43
20.09
14.29
30.70
growth rate 3.5% -16.7% 118.8% 26.0% 25.4% 38.8% -67.9% 3.4% -28.9% 114.8%
ROA 35.05
9.99
11.58
5.69
6.88
5.54
4.78
13.62
2.99
14.36
4.17
growth rate -71.5% 15.9% -50.9% 20.9% -19.5% -13.7% 184.9% -78.1% 380.3% -71.0%
ROE 78.36
20.30
23.42
13.25
17.81
13.36
10.75
29.28
7.21
38.18
10.48
growth rate -74.1% 15.4% -43.4% 34.4% -25.0% -19.5% 172.4% -75.4% 429.5% -72.6%
ROIC 53.33
14.89
17.60
9.79
12.31
9.43
7.83
20.91
5.28
24.69
6.46
growth rate -72.1% 18.2% -44.4% 25.7% -23.4% -17.0% 167.1% -74.8% 367.6% -73.8%
Cur. Ratio 2.21
1.97
1.97
1.15
1.52
1.73
1.30
1.55
1.55
1.61
1.60
growth rate -10.9% 0.0% -41.6% 32.2% 13.8% -24.9% 19.2% 0.0% 3.9% -0.6%
Quick Ratio 1.85
1.60
1.60
0.71
0.63
1.28
1.07
1.35
1.37
1.39
1.26
growth rate -13.5% 0.0% -55.6% -11.3% 103.2% -16.4% 26.2% 1.5% 1.5% -9.4%
Leverage 2.09
1.98
2.07
2.63
2.55
2.27
2.23
2.08
2.86
2.49
2.52
growth rate -5.3% 4.6% 27.1% -3.0% -11.0% -1.8% -6.7% 37.5% -12.9% 1.2%
Balance Sheet Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Acct.Receivable 0.00
0.00
2,950.98
1,346.59
1,332.40
3,212.00
4,117.00
4,916.00
5,609.00
5,747.00
7,685.00
growth rate -54.4% -1.1% 141.1% 28.2% 19.4% 14.1% 2.5% 33.7%
Acct.Payable 2,487.00
1,565.00
1,664.00
2,248.00
1,892.00
2,445.00
growth rate -37.1% 6.3% 35.1% -15.8% 29.2%
Cur.Assets 11,004.49
10,464.43
12,076.71
7,506.36
14,913.37
14,608.00
10,415.00
13,704.00
14,854.00
17,716.00
29,354.00
growth rate -4.9% 15.4% -37.8% 98.7% -2.1% -28.7% 31.6% 8.4% 19.3% 65.7%
Total Assets 24,446.71
24,500.32
25,993.55
28,301.19
30,425.93
33,749.00
31,748.00
33,707.00
33,551.00
34,986.00
129,944.00
growth rate 0.2% 6.1% 8.9% 7.5% 10.9% -5.9% 6.2% -0.5% 4.3% 271.4%
Cash 6,057.28
3,968.02
4,553.80
1,305.59
2,827.20
5,571.00
2,385.00
4,237.00
5,421.00
6,911.00
12,346.00
growth rate -34.5% 14.8% -71.3% 116.6% 97.1% -57.2% 77.7% 27.9% 27.5% 78.6%
Inventory 1,114.01
949.23
1,091.15
1,306.38
1,181.02
1,560.00
1,221.00
1,241.00
1,166.00
1,195.00
4,293.00
growth rate -14.8% 15.0% 19.7% -9.6% 32.1% -21.7% 1.6% -6.0% 2.5% 259.3%
Cur.Liabilities 4,977.17
5,313.03
6,133.75
6,527.16
9,807.70
8,461.00
8,017.00
8,841.00
9,563.00
10,654.00
18,304.00
growth rate 6.8% 15.5% 6.4% 50.3% -13.7% -5.3% 10.3% 8.2% 11.4% 71.8%
Liabilities 12,744.49
12,112.19
13,413.84
17,560.82
18,478.52
18,766.00
17,324.00
17,360.00
21,704.00
20,859.00
78,246.00
growth rate -5.0% 10.8% 30.9% 5.2% 1.6% -7.7% 0.2% 25.0% -3.9% 275.1%
LT Debt 4,832.89
4,200.60
4,238.44
5,178.21
6,292.22
7,245.00
6,558.00
5,716.00
6,975.00
5,661.00
43,388.00
growth rate -13.1% 0.9% 22.2% 21.5% 15.1% -9.5% -12.8% 22.0% -18.8% 666.4%
Equity 11,702.22
12,388.13
12,579.71
10,740.37
11,947.41
14,852.00
14,266.00
16,177.00
11,741.00
14,031.00
51,598.00
growth rate 5.9% 1.6% -14.6% 11.2% 24.3% -4.0% 13.4% -27.4% 19.5% 267.7%
Common Shares 1,974.00
1,727.00
1,717.00
1,688.00
1,662.00
1,670.00
1,679.00
1,680.00
1,652.00
1,637.00
1,712.00
growth rate -12.5% -0.6% -1.7% -1.5% 0.5% 0.5% 0.1% -1.7% -0.9% 4.6%
Cash Flow Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Capital Expenditures 136.39
334.28
289.34
432.04
423.37
526.00
820.00
1,215.00
1,055.00
951.00
836.00
growth rate 145.1% -13.4% 49.3% -2.0% 24.2% 55.9% 48.2% -13.2% -9.9% -12.1%
Cash Dividends 1,957.60
1,736.06
1,777.05
1,802.28
1,820.42
2,398.00
2,477.00
2,547.00
2,577.00
2,613.00
2,679.00
growth rate -11.3% 2.4% 1.4% 1.0% 31.7% 3.3% 2.8% 1.2% 1.4% 2.5%
Cash From OA 3,204.85
3,540.70
3,815.86
5,472.28
2,794.88
3,148.00
2,105.00
3,058.00
5,275.00
5,940.00
8,067.00
growth rate 10.5% 7.8% 43.4% -48.9% 12.6% -33.1% 45.3% 72.5% 12.6% 35.8%
FCF per Share 0.80
1.59
2.04
3.21
1.08
1.70
0.58
0.51
2.13
1.98
4.14
growth rate 98.8% 28.3% 57.4% -66.4% 57.4% -65.9% -12.1% 317.7% -7.0% 109.1%
Sale Purchase of Stock 288.00
-231.00
-231.00
-2,469.00
growth rate -100.0% 0.0% 0.0%
FCF 3,335.00
4,067.00
4,473.00
6,393.00
3,008.00
2,622.00
1,012.00
1,635.00
4,220.00
4,989.00
7,231.00
growth rate 22.0% 10.0% 42.9% -53.0% -12.8% -61.4% 61.6% 158.1% 18.2% 44.9%
Income Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Sales 14,828.23
15,361.19
16,748.77
13,892.40
12,917.93
15,879.00
16,560.00
19,427.00
20,776.00
22,561.00
26,145.00
growth rate 3.6% 9.0% -17.1% -7.0% 22.9% 4.3% 17.3% 6.9% 8.6% 15.9%
Op.Income 4,180.89
4,713.06
5,240.49
1,781.78
2,440.89
3,468.00
3,867.00
5,187.00
3,980.00
6,415.00
7,064.00
growth rate 12.7% 11.2% -66.0% 37.0% 42.1% 11.5% 34.1% -23.3% 61.2% 10.1%
IBT 4,416.62
4,786.38
5,503.82
1,844.86
2,279.26
2,381.00
2,077.00
5,915.00
5,131.00
5,968.00
4,975.00
growth rate 8.4% 15.0% -66.5% 23.6% 4.5% -12.8% 184.8% -13.3% 16.3% -16.6%
Net Income 8,366.50
2,445.62
2,924.18
1,545.26
2,020.67
2,004.00
1,565.00
4,457.00
1,007.00
4,920.00
3,439.00
growth rate -70.8% 19.6% -47.2% 30.8% -0.8% -21.9% 184.8% -77.4% 388.6% -30.1%
EPS 5.34
1.79
2.16
1.16
1.54
1.20
0.93
2.65
0.61
3.01
2.01
growth rate -66.5% 20.7% -46.3% 32.8% -22.1% -22.5% 185.0% -77.0% 393.4% -33.2%
Gross Profit 10,775.85
11,200.80
12,335.31
10,257.87
9,276.31
12,098.00
12,735.00
14,479.00
14,911.00
16,152.00
18,925.00
growth rate 3.9% 10.1% -16.8% -9.6% 30.4% 5.3% 13.7% 3.0% 8.3% 17.2%
R&D 2,875.29
2,811.43
3,026.67
3,077.91
2,941.52
3,913.00
4,037.00
4,477.00
6,085.00
5,118.00
5,891.00
growth rate -2.2% 7.7% 1.7% -4.4% 33.0% 3.2% 10.9% 35.9% -15.9% 15.1%

Quarterly Statements

Item Name Dec '18 Mar '19 Jun '19 Sep '19 Dec '19
Earnings BIT 1,634.00
1,788.00
2,078.00
1,810.00
1,388.00
growth rate 9.4% 16.2% -12.9% -23.3%
Balance Sheet Dec '18 Mar '19 Jun '19 Sep '19 Dec '19
Acct.Receivable 5,782.00
5,597.00
5,501.00
5,351.00
7,685.00
growth rate -3.2% -1.7% -2.7% 43.6%
Acct.Payable 1,892.00
1,976.00
2,005.00
1,888.00
2,445.00
growth rate 4.4% 1.5% -5.8% 29.5%
Cur.Assets 17,160.00
17,093.00
37,716.00
40,191.00
29,354.00
growth rate -0.4% 120.7% 6.6% -27.0%
Total Assets 34,986.00
34,834.00
55,163.00
57,433.00
129,944.00
growth rate -0.4% 58.4% 4.1% 126.3%
Cash 6,911.00
7,335.00
28,404.00
30,489.00
12,346.00
growth rate 6.1% 287.2% 7.3% -59.5%
Inventory 1,195.00
1,283.00
1,308.00
1,192.00
4,293.00
growth rate 7.4% 2.0% -8.9% 260.2%
Cur.Liabilities 10,654.00
8,841.00
9,711.00
10,489.00
18,304.00
growth rate -17.0% 9.8% 8.0% 74.5%
Liabilities 20,859.00
19,517.00
39,012.00
39,679.00
78,246.00
growth rate -6.4% 99.9% 1.7% 97.2%
LT Debt 5,646.00
5,635.00
24,433.00
24,392.00
43,388.00
growth rate -0.2% 333.6% -0.2% 77.9%
Equity 14,031.00
15,218.00
16,049.00
17,648.00
51,598.00
growth rate 8.5% 5.5% 10.0% 192.4%
Common Shares 221.00
221.00
221.00
221.00
292.00
growth rate 0.0% 0.0% 0.0% 32.1%
Cash Flow Statement Dec '18 Mar '19 Jun '19 Sep '19 Dec '19
Capital Expenditures 290.00
204.00
191.00
190.00
251.00
growth rate -29.7% -6.4% -0.5% 32.1%
Cash Dividends 653.00
669.00
671.00
671.00
668.00
growth rate 2.5% 0.3% 0.0% -0.5%
Cash From OA 2,429.00
1,390.00
2,083.00
2,556.00
2,038.00
growth rate -42.8% 49.9% 22.7% -20.3%
Sale Purchase of Stock
growth rate
FCF 2,139.00
1,186.00
1,892.00
2,366.00
1,787.00
growth rate -44.6% 59.5% 25.1% -24.5%
Income Statement Dec '18 Mar '19 Jun '19 Sep '19 Dec '19
Sales 5,973.00
5,920.00
6,273.00
6,007.00
7,945.00
growth rate -0.9% 6.0% -4.2% 32.3%
Op.Income 1,634.00
1,788.00
2,078.00
1,810.00
1,388.00
growth rate 9.4% 16.2% -12.9% -23.3%
IBT 1,505.00
1,979.00
1,776.00
1,349.00
-129.00
growth rate 31.5% -10.3% -24.0% -100.0%
Net Income 1,160.00
1,710.00
1,432.00
1,353.00
-1,056.00
growth rate 47.4% -16.3% -5.5% -100.0%
EPS
growth rate
Gross Profit 4,301.00
4,088.00
4,420.00
4,219.00
6,198.00
growth rate -5.0% 8.1% -4.6% 46.9%
R&D 1,358.00
1,300.00
1,284.00
1,362.00
1,945.00
growth rate -4.3% -1.2% 6.1% 42.8%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (74.13)

YOY Growth Grade:

D (42.70)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 25.81 25.81 29.85
EPS / Growth 2.01

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 40.0% 50.0% 59.6%
Future PE 25.81 28.50 58.29
Future EPS 58.14 115.91 215.54
Value Price
MOS %
370.93
615.1%
816.63
1,474.4%
3,105.39
5,886.9%
MOS Price 185.46 408.31 1,552.69
IRT 6.28 5.53 5.05

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.